

**General**

**Common Present on Admission Diagnosis**

|                          |  |         |
|--------------------------|--|---------|
| <input type="checkbox"/> | Acidosis   | Post-op |
| <input type="checkbox"/> | Acute Post-Hemorrhagic Anemia  | Post-op |
| <input type="checkbox"/> | Acute Renal Failure  | Post-op |
| <input type="checkbox"/> | Acute Respiratory Failure  | Post-op |
| <input type="checkbox"/> | Acute Thromboembolism of Deep Veins of Lower Extremities   | Post-op |
| <input type="checkbox"/> | Anemia   | Post-op |
| <input type="checkbox"/> | Bacteremia   | Post-op |
| <input type="checkbox"/> | Bipolar disorder, unspecified  | Post-op |
| <input type="checkbox"/> | Cardiac Arrest   | Post-op |
| <input type="checkbox"/> | Cardiac Dysrhythmia  | Post-op |
| <input type="checkbox"/> | Cardiogenic Shock  | Post-op |
| <input type="checkbox"/> | Decubitus Ulcer  | Post-op |
| <input type="checkbox"/> | Dementia in Conditions Classified Elsewhere  | Post-op |
| <input type="checkbox"/> | Disorder of Liver  | Post-op |
| <input type="checkbox"/> | Electrolyte and Fluid Disorder   | Post-op |
| <input type="checkbox"/> | Intestinal Infection due to Clostridium Difficile  | Post-op |
| <input type="checkbox"/> | Methicillin Resistant Staphylococcus Aureus Infection  | Post-op |
| <input type="checkbox"/> | Obstructive Chronic Bronchitis with Exacerbation   | Post-op |
| <input type="checkbox"/> | Other Alteration of Consciousness  | Post-op |
| <input type="checkbox"/> | Other and Unspecified Coagulation Defects  | Post-op |
| <input type="checkbox"/> | Other Pulmonary Embolism and Infarction  | Post-op |
| <input type="checkbox"/> | Phlebitis and Thrombophlebitis   | Post-op |
| <input type="checkbox"/> | Protein-calorie Malnutrition   | Post-op |
| <input type="checkbox"/> | Psychosis, unspecified psychosis type  | Post-op |
| <input type="checkbox"/> | Schizophrenia Disorder   | Post-op |
| <input type="checkbox"/> | Sepsis   | Post-op |
| <input type="checkbox"/> | Septic Shock   | Post-op |
| <input type="checkbox"/> | Septicemia   | Post-op |
| <input type="checkbox"/> | Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled | Post-op |
| <input type="checkbox"/> | Urinary Tract Infection, Site Not Specified  | Post-op |

**Elective Outpatient, Observation, or Admission (Single Response)**

|                          |   |  |
|--------------------------|---|--|
| <input type="checkbox"/> | Elective outpatient procedure: Discharge following routine recovery | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> | Outpatient observation services under general supervision           | Diagnosis:<br>Admitting Physician:<br>Patient Condition:<br>Bed request comments:<br>PACU & Post-op  |
| <input type="checkbox"/> | Outpatient in a bed - extended recovery                             | Diagnosis:<br>Admitting Physician:<br>Bed request comments:<br>PACU & Post-op  |
| <input type="checkbox"/> | Admit to Inpatient  | Diagnosis:<br>Admitting Physician:<br>Level of Care:<br>Patient Condition:<br>Bed request comments:<br>Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.<br>PACU & Post-op |

**Admission or Observation (Single Response)**

Patient has active outpatient status order on file

- |  |  |
|--|--|
| <input type="checkbox"/> Admit to Inpatient  | Diagnosis:<br>Admitting Physician:<br>Level of Care:<br>Patient Condition:<br>Bed request comments:<br>Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.<br>PACU & Post-op |
| <input type="checkbox"/> Outpatient observation services under general supervision | Diagnosis:<br>Admitting Physician:<br>Patient Condition:<br>Bed request comments:<br>PACU & Post-op  |
| <input type="checkbox"/> Outpatient in a bed - extended recovery                   | Diagnosis:<br>Admitting Physician:<br>Bed request comments:<br>PACU & Post-op  |
| <input type="checkbox"/> Transfer patient  | Level of Care:<br>Bed request comments:<br>Scheduling/ADT  |
| <input type="checkbox"/> Return to previous bed                                    | Routine, Until discontinued, Starting S, Scheduling/ADT  |

**Admission (Single Response)**

Patient has active status order on file

- |   |  |
|---|--|
| <input type="checkbox"/> Admit to inpatient     | Diagnosis:<br>Admitting Physician:<br>Level of Care:<br>Patient Condition:<br>Bed request comments:<br>Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.<br>PACU & Post-op |
| <input type="checkbox"/> Transfer patient       | Level of Care:<br>Bed request comments:<br>Scheduling/ADT  |
| <input type="checkbox"/> Return to previous bed | Routine, Until discontinued, Starting S, Scheduling/ADT  |

**Transfer (Single Response)**

Patient has active inpatient status order on file

- |   |   |
|---|---|
| <input type="checkbox"/> Transfer patient       | Level of Care:<br>Bed request comments:<br>Scheduling/ADT |
| <input type="checkbox"/> Return to previous bed | Routine, Until discontinued, Starting S, Scheduling/ADT   |

**Code Status**

- |   |  |
|---|--|
| <input type="checkbox"/> Full code                | Code Status decision reached by:<br>Post-op            |
| <input type="checkbox"/> DNR (Do Not Resuscitate) |  |
| <input type="checkbox"/> DNR (Do Not Resuscitate) | Does patient have decision-making capacity?<br>Post-op |

|   |  |
|---|--|
| <input type="checkbox"/> Consult to Palliative Care Service | Priority:<br>Reason for Consult?<br>Order?<br>Name of referring provider:<br>Enter call back number: |
| <input type="checkbox"/> Consult to Social Work             | Reason for Consult:<br>Post-op   |
| <input type="checkbox"/> Modified Code                      | Does patient have decision-making capacity?<br>Modified Code restrictions:<br>Post-op                |
| <input type="checkbox"/> Treatment Restrictions             | Treatment Restriction decision reached by:<br>Specify Treatment Restrictions:<br>Post-op             |

### Isolation

|  |         |
|--|---------|
| <input type="checkbox"/> Airborne isolation status | Details |
| <input type="checkbox"/> Contact isolation status  | Details |
| <input type="checkbox"/> Droplet isolation status  | Details |
| <input type="checkbox"/> Enteric isolation status  | Details |

### Precautions

|  |  |
|--|--|
| <input type="checkbox"/> Aspiration precautions      | Post-op  |
| <input checked="" type="checkbox"/> Fall precautions | Increased observation level needed:<br>Post-op |
| <input type="checkbox"/> Latex precautions           | Post-op  |
| <input type="checkbox"/> Seizure precautions         | Increased observation level needed:<br>Post-op |
| <input type="checkbox"/> Hip precautions - Anterior  | Precaution:<br>Anterior. , Post-op             |
| <input type="checkbox"/> Hip precautions - Posterior | Precaution:<br>Posterior. , Post-op            |

## Nursing

### Vital Signs

|  |  |
|--|--|
| <input type="checkbox"/> Vital signs - T/P/R/BP (Q15min)   | Routine, Every 15 min<br>Times 4, then every 30 minutes times 4, then every hour times 4, then every 4 hours times 24 hours, then every 8 hours if stable., PACU & Post-op |
| <input type="checkbox"/> Vital signs - T/P/R/BP (Q4 hours) | Routine, Every 4 hours, Post-op  |

### Activity

|   |  |
|---|--|
| <input type="checkbox"/> Up with assistance | Routine, As needed<br>Specify: Up with assistance<br>Post-op   |
| <input type="checkbox"/> Bed rest           | Routine, Until discontinued, Starting S, Post-op   |
| <input type="checkbox"/> Weight bearing     | Routine, Until discontinued, Starting S<br>Weight Bearing Status:<br>Extremity:<br>Post-op                             |
| <input type="checkbox"/> Up in chair        | Routine, As needed<br>Specify: Up in chair<br>Additional modifier: for meals<br>For all meals as tolerated.<br>Post-op |
| <input type="checkbox"/> Ambulate patient   | Routine, Every shift<br>Specify:<br>Day of surgery, Post-op  |

### Equipment

|  |   |
|--|---|
| <input type="checkbox"/> Abduction pillow while in bed | Routine, Once<br>Special Instructions:<br>Post-op   |
| <input type="checkbox"/> Overhead frame trapeze        | Routine, Once<br>Special Instructions:<br>Post-op   |
| <input type="checkbox"/> Commode at bedside            | Routine, Once<br>For total hip arthroplasty, Post-op  |
| <input type="checkbox"/> Obtain a hip abduction brace  | Routine, Until discontinued, Starting S<br>Set Flexion to *** degrees and Abduction to *** degrees.,<br>Post-op |
| <input type="checkbox"/> Knee immobilizer              | Routine, Once<br>Left/Right:<br>Sizes:<br>Gender Size:<br>Special Instructions: when out of bed<br>Post-op      |

### Nursing Assessments

|   |   |
|---|---|
| <input type="checkbox"/> Peripheral vascular assessment | Routine, Per unit protocol<br>Until discharge., Post-op |
|---|---|

### Nursing Interventions

|   |  |
|---|--|
| <input type="checkbox"/> Intake and output            | Routine, Every shift For 48 Hours, Post-op   |
| <input type="checkbox"/> Insert and Maintain Foley    |  |
| <input type="checkbox"/> Insert Foley catheter        | Routine, Once<br>Type:<br>Size:<br>Urinometer needed:<br>If unable to void., Post-op   |
| <input type="checkbox"/> Foley Catheter Care          | Routine, Until discontinued, Starting S For 48 Hours<br>Orders: to gravity<br>Post-op  |
| <input type="checkbox"/> Foley catheter - discontinue | Routine, Once, Starting S+1<br>Post-op day 1., Post-op   |
| <input type="checkbox"/> Place antiembolic stockings  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> Apply ice pack               | Routine, Until discontinued, Starting S<br>Affected area:<br>Waking hours only?<br>Nurse to schedule?<br>Special Instructions:<br>To affected extremity., Post-op    |
| <input type="checkbox"/> Elevate extremity            | Routine, Until discontinued, Starting S<br>Position:<br>Additional instructions: elevate extremity<br>Extremity:<br>Place pillows under affected extremity., Post-op |
| <input type="checkbox"/> Wound care orders            | Routine, Daily, Starting S+1<br>Wound care to be performed by:<br>Location:<br>Site:<br>Irrigate wound?<br>Apply:<br>Dressing Type:<br>POD #1 as needed., Post-op    |
| <input type="checkbox"/> Patient may shower           | Routine, Daily<br>Specify:<br>Additional modifier:<br>Post-op  |

### Diet

|  |  |
|--|--|
| <input type="checkbox"/> Diet - Clear liquids, advance as tolerated to Regular                             | Diet effective now, Starting S<br>Diet(s): Clear Liquids<br>Advance Diet as Tolerated? Yes<br>Target Diet: Regular<br>Advance target diet criteria:<br>Liquid Consistency:<br>Fluid Restriction:<br>Foods to Avoid:<br>Please assess bowel sounds between progressions., Post-op                             |
| <input type="checkbox"/> Diet - Clear liquids, advance as tolerated to Diabetic 1800 Carb Control          | Diet effective now, Starting S<br>Diet(s): Clear Liquids<br>Advance Diet as Tolerated? Yes<br>Target Diet: Diabetic 1800 Carb Control<br>Advance target diet criteria:<br>Liquid Consistency:<br>Fluid Restriction:<br>Foods to Avoid:<br>Please assess bowel sounds between progressions., Post-op          |
| <input type="checkbox"/> Diet - Clear liquids, advance as tolerated to Heart Healthy                       | Diet effective now, Starting S<br>Diet(s): Clear Liquids<br>Advance Diet as Tolerated? Yes<br>Target Diet: Heart Healthy<br>Advance target diet criteria:<br>Liquid Consistency:<br>Fluid Restriction:<br>Foods to Avoid:<br>Please assess bowel sounds between progressions., Post-op                       |
| <input type="checkbox"/> Diet - Clear liquids, advance as tolerated to Renal (80GM Pro, 2-3GM Na, 2-3GM K) | Diet effective now, Starting S<br>Diet(s): Clear Liquids<br>Advance Diet as Tolerated? Yes<br>Target Diet: Renal (80GM Pro, 2-3GM Na, 2-3GM K)<br>Advance target diet criteria:<br>Liquid Consistency:<br>Fluid Restriction:<br>Foods to Avoid:<br>Please assess bowel sounds between progressions., Post-op |

**Notify**

|   |  |
|---|--|
| <input type="checkbox"/> Notify Hospitalist/Internist of patient's location | Routine, Once For 1 Occurrences, Post-op |
|---|--|

**IV Fluids**

**Peripheral IV Access**

|   |  |
|---|--|
| <input checked="" type="checkbox"/> Initiate and maintain IV    |  |
| <input checked="" type="checkbox"/> Insert peripheral IV        | Routine, Once, PACU & Post-op                                |
| <input checked="" type="checkbox"/> sodium chloride 0.9 % flush | 10 mL, intravenous, every 12 hours scheduled, PACU & Post-op |
| <input checked="" type="checkbox"/> sodium chloride 0.9 % flush | 10 mL, intravenous, PRN, line care, PACU & Post-op           |

**IV Fluids (Single Response)**

|   |  |
|---|--|
| <input type="checkbox"/> sodium chloride 0.9 % infusion | 75 mL/hr, intravenous, continuous, Post-op |
| <input type="checkbox"/> lactated Ringer's infusion     | 75 mL/hr, intravenous, continuous, Post-op |

**Medications**

**IV Antibiotics: For Patients LESS than or EQUAL to 120 kg**

|   |  |
|---|--|
| <input type="checkbox"/> cefazolin (ANCEF) IV - For Patients LESS than or EQUAL to 120 kg | 2 g, intravenous, once, For 1 Doses, Post-op<br>For patients LESS than or EQUAL to 120 kg<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis |
|---|--|

|  |  |
|--|--|
| <input type="checkbox"/> clindamycin (CLEOCIN) IV - For Penicillin Allergic Patients | 900 mg, intravenous, for 30 Minutes, once, For 1 Doses, Post-op<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis |
| <input type="checkbox"/> vancomycin (VANCOCIN) IV                                    | 15 mg/kg, intravenous, once, For 1 Doses, Post-op<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis               |

**IV Antibiotics: For Patients GREATER than 120 kg**

|  |  |
|--|--|
| <input type="checkbox"/> cefazolin (ANCEF) IV - For Patients GREATER than 120 kg     | 3 g, intravenous, once, For 1 Doses, Post-op<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis                    |
| <input type="checkbox"/> clindamycin (CLEOCIN) IV - For Penicillin Allergic Patients | 900 mg, intravenous, for 30 Minutes, once, For 1 Doses, Post-op<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis |
| <input type="checkbox"/> vancomycin (VANCOCIN) IV                                    | 15 mg/kg, intravenous, once, For 1 Doses, Post-op<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis               |

**Scheduled Pain: For Patients LESS than 70 years old**

|   |  |
|---|--|
| <input type="checkbox"/> HYDROcodone-acetaminophen (NORCO) 5-325 mg per tablet  | 1 tablet, oral, once, For 1 Doses, Post-op                                       |
| <input type="checkbox"/> traMADol (ULTRAM) tablet - For eGFR LESS than 30 mL/min, change frequency to every 12 hours                                    | 50 mg, oral, every 6 hours, Post-op<br>(Max Daily dose not to exceed 200 mg/day) |
| <input type="checkbox"/> Subsequent Doses following Surgery: pregabalin (LYRICA) 75 mg tablet OR gabapentin (NEURONTIN) 400 mg tablet (Single Response) |  |
| <input type="checkbox"/> pregabalin (LYRICA) capsule  | 75 mg, oral, 2 times daily, Post-op  |
| <input type="checkbox"/> gabapentin (NEURONTIN) tablet  | 400 mg, oral, 2 times daily, Post-op   |

**Scheduled Pain: For Patients GREATER than 70 years old**

|   |   |
|---|---|
| <input type="checkbox"/> HYDROcodone-acetaminophen (NORCO) 5-325 mg per tablet  | 1 tablet, oral, once, For 1 Doses, Post-op  |
| <input type="checkbox"/> Subsequent Doses following Surgery: pregabalin (LYRICA) 50 mg tablet OR gabapentin (NEURONTIN) 300 mg tablet (Single Response) |   |
| <input type="checkbox"/> pregabalin (LYRICA) capsule  | 50 mg, oral, 2 times daily, PACU & Post-op  |
| <input type="checkbox"/> gabapentin (NEURONTIN) tablet  | 300 mg, oral, 2 times daily, PACU & Post-op |

**PRN Mild Pain (Pain Score 1-3) (Single Response)**  
(adjust dose for renal/liver function and age)

|  |  |
|--|--|
| <input type="checkbox"/> acetaminophen (TYLENOL) tablet OR oral solution | <b>"Or" Linked Panel</b><br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources)   |
| <input type="checkbox"/> acetaminophen (TYLENOL) tablet                  | 650 mg, oral, every 6 hours PRN, mild pain (score 1-3), Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. Give the tablet if the patient can tolerate oral medication. (Cirrhosis patients maximum: 2 grams per day from all sources) |
| <input type="checkbox"/> acetaminophen (TYLENOL)suspension               | 650 mg, oral, every 6 hours PRN, mild pain (score 1-3), Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Use if patient cannot tolerate oral tablet.                 |

**PRN Oral for Moderate Pain (Pain Score 4-6): For Patients GREATER than 65 years old (Single Response)**

(adjust dose for renal/liver function and age)

|  |   |
|--|---|
| <b>( ) acetaminophen-codeine (TYLENOL #3) tablet OR elixir "Or" Linked Panel</b>   |   |
| Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) |   |
| <input type="checkbox"/> acetaminophen-codeine (TYLENOL #3) 300-30 mg per tablet   | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Give if patient is able to tolerate oral medication. |
| <input type="checkbox"/> acetaminophen-codeine 300 mg-30 mg /12.5 mL solution  | 12.5 mL, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) Use if patient cannot swallow tablet.                  |
| <b>( ) HYDROcodone-acetaminophen 5/325 (NORCO) tablet OR elixir "Or" Linked Panel</b>  |   |
| Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) |   |
| <input type="checkbox"/> HYDROcodone-acetaminophen (NORCO) 5-325 mg per tablet   | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6)  |
| <input type="checkbox"/> HYDROcodone-acetaminophen (HYCET) 2.5-108.3 mg/5 mL solution  | 10 mL, oral, every 6 hours PRN, moderate pain (score 4-6)   |
| <b>( ) traMADol (ULTRAM) tablet - For eGFR LESS than 30 mL/min, change frequency to every 12 hours)</b>                      | <b>25 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op<br/>(Max Daily dose not to exceed 200 mg/day). Give if patient can tolerate oral medication.</b>  |

**PRN Oral for Moderate Pain (Pain Score 4-6): For Patients LESS than 65 years old (Single Response)**  
(adjust dose for renal/liver function and age)

|  |   |
|--|---|
| <b>( ) acetaminophen-codeine (TYLENOL #3) tablet OR elixir "Or" Linked Panel</b>   |   |
| Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) |   |
| <input type="checkbox"/> acetaminophen-codeine (TYLENOL #3) 300-30 mg per tablet   | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Give if patient is able to tolerate oral medication. |
| <input type="checkbox"/> acetaminophen-codeine 300 mg-30 mg /12.5 mL solution  | 12.5 mL, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) Use if patient cannot swallow tablet.                  |
| <b>( ) HYDROcodone-acetaminophen 5/325 (NORCO) tablet OR elixir "Or" Linked Panel</b>  |   |
| Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) |   |
| <input type="checkbox"/> HYDROcodone-acetaminophen (NORCO) 5-325 mg per tablet   | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6)  |
| <input type="checkbox"/> HYDROcodone-acetaminophen (HYCET) 2.5-108.3 mg/5 mL solution  | 10 mL, oral, every 6 hours PRN, moderate pain (score 4-6)   |
| <b>( ) HYDROcodone-acetaminophen 7.5/325 (NORCO) tablet OR elixir "Or" Linked Panel</b>                                      |   |

Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources)

|  |   |
|--|---|
| <input type="checkbox"/> HYDROcodone-acetaminophen (NORCO) 7.5-325 mg per tablet | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Give if patient is able to tolerate oral medication. |
|--|---|

|  |  |
|--|--|
| <input type="checkbox"/> HYDROcodone-acetaminophen (HYCET) 7.5-325 mg/15 mL solution | 15 mL, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) Use if patient cannot swallow tablet. |
|--|--|

HYDROcodone-acetaminophen 10/325 (NORCO) tablet OR elixir **"Or" Linked Panel**

Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources)

|  |   |
|--|---|
| <input type="checkbox"/> HYDROcodone-acetaminophen (NORCO 10-325) 10-325 mg per tablet | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Give if patient is able to tolerate oral medication. |
|--|---|

|  |   |
|--|---|
| <input type="checkbox"/> HYDROcodone-acetaminophen (HYCET) 7.5-325 mg/15 mL solution | 20 mL, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources) Use if patient can not swallow tablet. |
|--|---|

traMADol (ULTRAM) tablet - For eGFR LESS than 30 mL/min, change frequency to every 12 hours) 50 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op  
(Max Daily dose not to exceed 200 mg/day).

Give if patient is able to tolerate oral medication

#### PRN IV for Moderate Pain (Pain Score 4-6): For Patients GREATER than 65 years old (Single Response)

If you select a PCA option you will not be allowed to also order IV PRN pain medications from this section.  
(adjust dose for renal/liver function and age)

|  |   |
|--|---|
| <input type="checkbox"/> fentaNYL (SUBLIMAZE) injection  | 12.5 mcg, intravenous, every 2 hour PRN, moderate pain (score 4-6), Post-op<br>Use if patient is unable to swallow or faster onset is needed  |
| <input type="checkbox"/> morphine 2 mg/mL injection  | 1 mg, intravenous, every 3 hours PRN, moderate pain (score 4-6), Post-op<br>Use if patient is unable to swallow or faster onset is needed   |
| <input type="checkbox"/> HYDROmorphine (DILAUDID) injection  | 0.2 mg, intravenous, every 3 hours PRN, moderate pain (score 4-6), Post-op<br>Use if patient is unable to swallow or faster onset is needed   |
| <input type="checkbox"/> ketorolac (TORADOL) injection - Do not use in patients with eGFR LESS than 30 mL/min. | 15 mg, intravenous, every 6 hours PRN, moderate pain (score 4-6), For 5 Days, Post-op<br>Do not use in patients with eGFR LESS than 30 mL/min. Use if patient is unable to swallow or faster onset is needed. |

#### PRN IV for Moderate Pain (Pain Score 4-6): For Patients LESS than 65 years old (Single Response)

If you select a PCA option you will not be allowed to also order IV PRN pain medications from this section.  
(adjust dose for renal/liver function and age)

|   |  |
|---|--|
| <input type="checkbox"/> fentaNYL (SUBLIMAZE) injection | 25 mcg, intravenous, every 2 hour PRN, moderate pain (score 4-6), Post-op<br>Use if patient is unable to swallow or faster onset is needed |
|---|--|



|   |  |
|---|--|
| ( ) morphine 2 mg/mL injection  | 2 mg, intravenous, every 3 hours PRN, moderate pain (score 4-6), Post-op<br>Use if patient is unable to swallow or faster onset is needed  |
| ( ) HYDROmorphine (DILAUDID) injection  | 0.5 mg, intravenous, every 3 hours PRN, moderate pain (score 4-6), Post-op<br>Use if patient is unable to swallow or faster onset is needed  |
| ( ) ketorolac (TORADOL) IV (Single Response)  | Do NOT use in patients with eGFR LESS than 30 mL/min AND/OR patients LESS than 17 years of age.<br>WARNING: Use is contraindicated for treatment of perioperative pain OR in the setting of coronary artery bypass graft (CABG) surgery. |
| ( ) For patients ages GREATER than 64 OR weight LESS than 50 kg OR eGFR 30-59 mL/min - ketorolac (TORADOL) injection              | 15 mg, intravenous, every 6 hours PRN, moderate pain (score 4-6), For 5 Days   |
| ( ) For patients ages 17-64 AND weight GREATER than or EQUAL to 50 kg AND eGFR at least 60 mL/min - ketorolac (TORADOL) injection | 30 mg, intravenous, every 6 hours PRN, moderate pain (score 4-6), For 5 Days   |

**PRN Oral for Severe Pain (Pain Score 7-10): For Patients GREATER than 65 years old (Single Response)**  
(adjust dose for renal/liver function and age)

|   |   |
|---|---|
| ( ) HYDROcodone-acetaminophen (NORCO) 7.5-325 mg per tablet       | 1 tablet, oral, every 6 hours PRN, severe pain (score 7-10), Post-op<br>Give if patient is able to tolerate oral medication |
| ( ) HYDROcodone-acetaminophen (NORCO 10-325) 10-325 mg per tablet | 1 tablet, oral, every 6 hours PRN, severe pain (score 7-10), Post-op<br>Give if patient is able to tolerate oral medication |
| ( ) HYDROmorphine (DILAUDID) tablet                               | 2 mg, oral, every 6 hours PRN, severe pain (score 7-10), Post-op<br>Give if patient is able to tolerate oral medication     |
| ( ) morphine (MSIR) tablet  | 15 mg, oral, every 6 hours PRN, severe pain (score 7-10), Post-op<br>Give if patient is able to tolerate oral medication    |
| ( ) oxyCODONE (ROXICODONE) immediate release tablet               | 5 mg, oral, every 6 hours PRN, severe pain (score 7-10), Post-op<br>Give if patient is able to tolerate oral medication     |

**PRN Oral for Severe Pain (Pain Score 7-10): For Patients LESS than 65 years old (Single Response)**  
(adjust dose for renal/liver function and age)

|   |  |
|---|--|
| ( ) HYDROmorphine (DILAUDID) tablet                 | 2 mg, oral, every 6 hours PRN, severe pain (score 7-10), Post-op<br>Give if patient is able to tolerate oral medication  |
| ( ) morphine (MSIR) tablet                          | 15 mg, oral, every 6 hours PRN, severe pain (score 7-10), Post-op<br>Give if patient is able to tolerate oral medication |
| ( ) oxyCODONE (ROXICODONE) immediate release tablet | 10 mg, oral, every 6 hours PRN, severe pain (score 7-10), Post-op<br>Give if patient is able to tolerate oral medication |

**PRN IV for Severe Pain (Pain Score 7-10): For Patients LESS than 65 years old (Single Response)**

If you select a PCA option you will not be allowed to also order IV PRN pain medications from this section.  
(adjust dose for renal/liver function and age)

|                                    |  |
|------------------------------------|--|
| ( ) fentaNYL (SUBLIMAZE) injection | 50 mcg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op<br>Use if patient is unable to swallow or faster onset is needed |
| ( ) morphine injection             | 4 mg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op<br>Use if patient is unable to swallow or faster onset is needed   |

|   |  |
|---|--|
| <input type="checkbox"/> HYDROmorphone (DILAUDID) injection | 0.8 mg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op<br>Use if patient is unable to swallow or faster onset is needed |
|---|--|

**PRN IV for Severe Pain (Pain Score 7-10): For Patients GREATER than 65 years old (Single Response)**

If you select a PCA option you will not be allowed to also order IV PRN pain medications from this section.  
(adjust dose for renal/liver function and age)

|   |  |
|---|--|
| <input type="checkbox"/> fentaNYL (SUBLIMAZE) injection     | 25 mcg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op<br>Use if patient is unable to swallow or faster onset is needed |
| <input type="checkbox"/> morphine injection                 | 2 mg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op<br>Use if patient is unable to swallow or faster onset is needed   |
| <input type="checkbox"/> HYDROmorphone (DILAUDID) injection | 0.5 mg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op<br>Use if patient is unable to swallow or faster onset is needed |

**PCA Medications (Single Response)**

|  |   |
|--|---|
| <input type="checkbox"/> morPHINE PCA 30 mg/30 mL          | Loading Dose (optional): Not Ordered<BR>PCA Dose: 1 mg<BR>Lockout: Not Ordered<BR>Continuous Dose: 0 mg/hr<BR>MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op<br>Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors. |
| <input type="checkbox"/> morPHINE 30 mg/30 mL PCA          |   |
| <input type="checkbox"/> Vital signs - T/P/R/BP            | Routine, Per unit protocol<br>- Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then<br>- Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then<br>- Every 4 hours until PCA therapy is discontinued.<br>- Immediately following PCA administration tubing change, Post-op   |
| <input type="checkbox"/> Richmond agitation sedation scale | Routine, Once<br>Hold infusion daily at:<br>Target RASS:<br>BIS Monitoring (Target BIS: 40-60):<br>60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op  |
| <input type="checkbox"/> Notify Physician (Specify)        | Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason<br>- Inadequate analgesia<br>- Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy<br>- PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op   |

|   |  |
|---|--|
| <input type="checkbox"/> Stop the PCA pump and call ordering physician and/or CERT team for any of the following: | Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less<br>- Severe and/or recent confusion or disorientation<br>- POSS sedation level 4: Somnolent and difficult to arouse<br>- Sustained hypotension (SBP less than 90)<br>- Excessive nausea or vomiting<br>- Urinary retention, Post-op  |
| <input type="checkbox"/> naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg   | 0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., For 1 Doses, Post-op<br>Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.   |
| <input type="checkbox"/> hydromorPHONE PCA (DILAUDID) 15 mg/30 mL   | Loading Dose (optional): Not Ordered<BR>PCA Dose: 0.2 mg<BR>Lockout: Not Ordered<BR>Continuous Dose: 0 mg/hr<BR>MAX (Four hour dose limit): 3 mg intravenous, continuous, Post-op<br>Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26662::"0.2"} mg every {Bolus Frequency:26663::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26664::"0.1"} mg ONCE. Adjust doses for age, renal function or other factors.<br>Turn Off PCA Continuous Dose (Basal Rate) On Date:<br>Turn Off PCA Continuous Dose (Basal Rate) At Time: |
| <input type="checkbox"/> Vital signs - T/P/R/BP   | Routine, Per unit protocol<br>- Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then<br>- Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then<br>- Every 4 hours until PCA therapy is discontinued.<br>- Immediately following PCA administration tubing change, Post-op  |
| <input type="checkbox"/> Richmond agitation sedation scale  | Routine, Once<br>Hold infusion daily at:<br>Target RASS:<br>BIS Monitoring (Target BIS: 40-60):<br>60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op   |
| <input type="checkbox"/> Notify Physician (Specify)   | Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason<br>- Inadequate analgesia<br>- Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy<br>- PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op  |
| <input type="checkbox"/> Stop the PCA pump and call ordering physician and/or CERT team for any of the following: | Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less<br>- Severe and/or recent confusion or disorientation<br>- POSS sedation level 4: Somnolent and difficult to arouse<br>- Sustained hypotension (SBP less than 90)<br>- Excessive nausea or vomiting<br>- Urinary retention, Post-op  |

|   |  |
|---|--|
| <input type="checkbox"/> naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg   | 0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., For 1 Doses, Post-op<br>Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.   |
| <input type="checkbox"/> fentaNYL PCA (SUBLIMAZE) 1500 mcg/30 mL  | Loading Dose (optional): Not Ordered<BR>PCA Dose: 10 mcg<BR>Lockout (recommended 6-8 min): Not Ordered<BR>Continuous Dose: 0 mcg/hr<BR>MAX (Four hour dose limit): 150 mcg<br>intravenous, continuous, Post-op<br>Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patient 19-59 years old, may bolus {Bolus Dose:26656::"25"} mcg every {Bolus Frequency:26655::"2"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26654::"10"} mcg ONCE. Adjust doses for age, renal function or other factors. |
| <input type="checkbox"/> Vital signs - T/P/R/BP   | Turn Off PCA Continuous Dose (Basal Rate) On Date:<br>Turn Off PCA Continuous Dose (Basal Rate) At Time:<br>Routine, Per unit protocol<br>- Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then<br>- Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then<br>- Every 4 hours until PCA therapy is discontinued.<br>- Immediately following PCA administration tubing change, Post-op  |
| <input type="checkbox"/> Richmond agitation sedation scale  | Routine, Once<br>Hold infusion daily at:<br>Target RASS:<br>BIS Monitoring (Target BIS: 40-60):<br>60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op   |
| <input type="checkbox"/> Notify Physician (Specify)   | Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason<br>- Inadequate analgesia<br>- Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy<br>- PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op  |
| <input type="checkbox"/> Stop the PCA pump and call ordering physician and/or CERT team for any of the following: | Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less<br>- Severe and/or recent confusion or disorientation<br>- POSS sedation level 4: Somnolent and difficult to arouse<br>- Sustained hypotension (SBP less than 90)<br>- Excessive nausea or vomiting<br>- Urinary retention, Post-op  |

naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg

0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., For 1 Doses, Post-op  
Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.

### PCA Medications (Single Response)

( ) morPHINE PCA 30 mg/30 mL

morPHINE 30 mg/30 mL PCA

Loading Dose (optional): Not Ordered<BR>PCA Dose: 1 mg<BR>Lockout: Not Ordered<BR>Continuous Dose: 0 mg/hr<BR>MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op  
Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.

Vital signs - T/P/R/BP

Routine, Per unit protocol  
- Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then  
- Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then  
- Every 4 hours until PCA therapy is discontinued.  
- Immediately following PCA administration tubing change, Post-op

Richmond agitation sedation scale

Routine, Once  
Hold infusion daily at:  
Target RASS:  
BIS Monitoring (Target BIS: 40-60):  
60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op

Notify Physician (Specify)

Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason  
- Inadequate analgesia  
- Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy  
- PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op

Stop the PCA pump and call ordering physician and/or CERT team for any of the following:

Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less  
- Severe and/or recent confusion or disorientation  
- POSS sedation level 4: Somnolent and difficult to arouse  
- Sustained hypotension (SBP less than 90)  
- Excessive nausea or vomiting  
- Urinary retention, Post-op

|  |  |
|--|--|
| [ ] naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg   | 0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., For 1 Doses, Post-op<br>Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.   |
| () hydromorPHONE PCA (DILAUDID) 15 mg/30 mL  | Loading Dose (optional): Not Ordered<BR>PCA Dose: 0.2 mg<BR>Lockout: Not Ordered<BR>Continuous Dose: 0 mg/hr<BR>MAX (Four hour dose limit): 3 mg intravenous, continuous, Post-op<br>Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26662::"0.2"} mg every {Bolus Frequency:26663::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26664::"0.1"} mg ONCE. Adjust doses for age, renal function or other factors. Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time: |
| [ ] hydromorPHONE (DILAUDID) 15 mg/30 mL PCA   |  |
| [ ] Vital signs - T/P/R/BP   | Routine, Per unit protocol<br>- Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then<br>- Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then<br>- Every 4 hours until PCA therapy is discontinued.<br>- Immediately following PCA administration tubing change, Post-op  |
| [ ] Richmond agitation sedation scale  | Routine, Once<br>Hold infusion daily at:<br>Target RASS:<br>BIS Monitoring (Target BIS: 40-60):<br>60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op   |
| [ ] Notify Physician (Specify)   | Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason<br>- Inadequate analgesia<br>- Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy<br>- PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op  |
| [ ] Stop the PCA pump and call ordering physician and/or CERT team for any of the following: | Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less<br>- Severe and/or recent confusion or disorientation<br>- POSS sedation level 4: Somnolent and difficult to arouse<br>- Sustained hypotension (SBP less than 90)<br>- Excessive nausea or vomiting<br>- Urinary retention, Post-op  |
| [ ] naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg   | 0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., For 1 Doses, Post-op<br>Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.   |

|  |  |
|--|--|
| <input type="checkbox"/> fentaNYL PCA (SUBLIMAZE) 600 mcg/30 mL<br><input type="checkbox"/> fentaNYL (SUBLIMAZE) 600 mcg/30 mL PCA | <p>Loading Dose (optional): Not Ordered&lt;BR&gt;PCA Dose: 10 mcg&lt;BR&gt;Lockout Interval: Not Ordered&lt;BR&gt;Continuous Dose: 0 mcg/hr&lt;BR&gt;MAX (Four hour dose limit): 150 mcg intravenous, continuous, Post-op</p> <p>Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patient 19-59 years old, may bolus {Bolus Dose:26656::"25"} mcg every {Bolus Frequency:26655::"2"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26654::"10"} mcg ONCE. Adjust doses for age, renal function or other factors.</p> <p>Turn Off PCA Continuous Dose (Basal Rate) On Date:<br/>Turn Off PCA Continuous Dose (Basal Rate) At Time:</p> |
| <input type="checkbox"/> Vital signs - T/P/R/BP  | <p>Routine, Per unit protocol</p> <ul style="list-style-type: none"> <li>- Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then</li> <li>- Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then</li> <li>- Every 4 hours until PCA therapy is discontinued.</li> <li>- Immediately following PCA administration tubing change, Post-op</li> </ul>  |
| <input type="checkbox"/> Richmond agitation sedation scale   | <p>Routine, Once</p> <p>Hold infusion daily at:</p> <p>Target RASS:</p> <p>BIS Monitoring (Target BIS: 40-60):</p> <p>60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op</p>  |
| <input type="checkbox"/> Notify Physician (Specify)  | <p>Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason</p> <ul style="list-style-type: none"> <li>- Inadequate analgesia</li> <li>- Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy</li> <li>- PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op</li> </ul>  |
| <input type="checkbox"/> Stop the PCA pump and call ordering physician and/or CERT team for any of the following:                  | <p>Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less</p> <ul style="list-style-type: none"> <li>- Severe and/or recent confusion or disorientation</li> <li>- POSS sedation level 4: Somnolent and difficult to arouse</li> <li>- Sustained hypotension (SBP less than 90)</li> <li>- Excessive nausea or vomiting</li> <li>- Urinary retention, Post-op</li> </ul>  |
| <input type="checkbox"/> naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg  | <p>0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., For 1 Doses, Post-op</p> <p>Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.</p>  |

**Antiemetics - HMH, HMSJ, HMW, HMSTC, HMTW Only**

|   |  |
|---|--|
| <input checked="" type="checkbox"/> ondansetron (ZOFTRAN) IV or Oral                    | <b>"Or" Linked Panel</b>   |
| <input checked="" type="checkbox"/> ondansetron ODT (ZOFTRAN-ODT) disintegrating tablet | 4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op<br>Give if patient is able to tolerate oral medication. |

|   |  |
|---|--|
| [X] ondansetron (ZOFTRAN) 4 mg/2 mL injection     | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op<br>Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.   |
| [X] promethazine (PHENERGAN) IV or Oral or Rectal | <b>"Or" Linked Panel</b>   |
| [X] promethazine (PHENERGAN) 12.5 mg IV           | 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. |
| [X] promethazine (PHENERGAN) tablet               | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is able to tolerate oral medication.   |
| [X] promethazine (PHENERGAN) suppository          | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is UNable to tolerate oral medication.   |

#### Antiemetics - HMSTJ Only

|  |  |
|--|--|
| [X] ondansetron (ZOFTRAN) IV or Oral                                   | <b>"Or" Linked Panel</b>   |
| [X] ondansetron ODT (ZOFTRAN-ODT) disintegrating tablet                | 4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op<br>Give if patient is able to tolerate oral medication.   |
| [X] ondansetron (ZOFTRAN) 4 mg/2 mL injection                          | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op<br>Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.   |
| [X] promethazine (PHENERGAN) IVPB or Oral or Rectal                    | <b>"Or" Linked Panel</b>   |
| [X] promethazine (PHENERGAN) 25 mg in sodium chloride 0.9 % 50 mL IVPB | 12.5 mg, intravenous, for 30 Minutes, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. |
| [X] promethazine (PHENERGAN) tablet                                    | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is able to tolerate oral medication.   |
| [X] promethazine (PHENERGAN) suppository                               | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is UNable to tolerate oral medication.   |

#### Antiemetics - HMSL, HMWB Only

|  |  |
|--|--|
| [X] ondansetron (ZOFTRAN) IV or Oral   | <b>"Or" Linked Panel</b>   |
| [X] ondansetron ODT (ZOFTRAN-ODT) disintegrating tablet  | 4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op<br>Give if patient is able to tolerate oral medication.   |
| [X] ondansetron (ZOFTRAN) 4 mg/2 mL injection  | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op<br>Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.   |
| [X] promethazine (PHENERGAN) IV or Oral or Rectal  | <b>"Or" Linked Panel</b>   |
| [X] promethazine (PHENERGAN) 12.5 mg in sodium chloride 0.9 % 0.9 % 20 mL for Alaris pump syringe option | 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. |
| [X] promethazine (PHENERGAN) tablet  | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is able to tolerate oral medication.   |
| [X] promethazine (PHENERGAN) suppository   | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is UNable to tolerate oral medication.   |



**Bowel Care (Single Response)**

|   |   |
|---|---|
| <input type="checkbox"/> sennosides-docusate sodium (SENOKOT-S) 8.6-50 mg per tablet                                    | 2 tablet, oral, nightly PRN, constipation, Post-op  |
| <input type="checkbox"/> simethicone (MYLICON) chewable tablet  | 160 mg, oral, 4 times daily PRN, flatulence, Post-op  |
| <input type="checkbox"/> docusate sodium (COLACE) capsule   | 100 mg, oral, 2 times daily PRN, constipation, Post-op  |
| <input type="checkbox"/> magnesium hydroxide suspension - NOT RECOMMENDED FOR CHRONIC KIDNEY DISEASE STAGE 3 OR GREATER | 30 mL, oral, every 12 hours PRN, constipation, Post-op<br>Do not give if patient is on hemodialysis or is in chronic renal failure. |
| <input type="checkbox"/> bisacodyl (DULCOLAX) EC tablet   | 10 mg, oral, daily PRN, constipation, Post-op   |
| <input type="checkbox"/> bisacodyl (DULCOLAX) suppository   | 10 mg, rectal, daily PRN, constipation, Post-op   |

**Itching: For Patients LESS than 70 years old (Single Response)**

|   |  |
|---|--|
| <input type="checkbox"/> diphenhydrAMINE (BENADRYL) tablet  | 25 mg, oral, every 6 hours PRN, itching, Post-op |
| <input type="checkbox"/> hydrOXYzine (ATARAX) tablet  | 10 mg, oral, every 6 hours PRN, itching, Post-op |
| <input type="checkbox"/> cetirizine (ZyrTEC) tablet   | 5 mg, oral, daily PRN, itching, Post-op          |
| <input type="checkbox"/> fexofenadine (ALLEGRA) tablet - For eGFR LESS than 80 mL/min, reduce frequency to once daily as needed | 60 mg, oral, 2 times daily PRN, itching, Post-op |

**Itching: For Patients between 70-76 years old (Single Response)**

|   |   |
|---|---|
| <input type="checkbox"/> cetirizine (ZyrTEC) tablet | 5 mg, oral, daily PRN, itching, Post-op |
|---|---|

**Itching: For Patients GREATER than 77 years old (Single Response)**

|   |   |
|---|---|
| <input type="checkbox"/> cetirizine (ZyrTEC) tablet | 5 mg, oral, daily PRN, itching, Post-op |
|---|---|

**Insomnia**

|   |   |
|---|---|
| <input type="checkbox"/> ramelteon (ROZEREM) tablet | 8 mg, oral, nightly PRN, sleep, Post-op |
|---|---|

**VTE****DVT Risk and Prophylaxis Tool (Single Response)**

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

Low Risk of DVT

Low Risk (Single Response)

Low risk of VTE  
Routine, Once  
Low risk: Due to low risk, no VTE prophylaxis is needed.  
Will encourage early ambulation  
PACU & Post-op

Moderate Risk of DVT - Surgical

Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated.

|                          |   |  |
|--------------------------|---|--|
| <input type="checkbox"/> | Moderate Risk   |  |
| <input type="checkbox"/> | Moderate risk of VTE  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> | Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)  |  |
| <input type="checkbox"/> | Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> | Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> | enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> | enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1   |
| <input type="checkbox"/> | enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> | enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                 | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   |
| <input type="checkbox"/> | enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> | fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> | heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op   |
| <input type="checkbox"/> | heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> | warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> | Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> | Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> | Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> | Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> | Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> | Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> | Place antiembolic stockings   | Routine, Once, PACU & Post-op  |

Moderate Risk of DVT - Non-Surgical

Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated.

|  |  |
|--|--|
| <input type="checkbox"/> Moderate Risk   |  |
| <input type="checkbox"/> Moderate risk of VTE  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)                                    |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                 | 30 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op  |

High Risk of DVT - Surgical

Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis.

High Risk

High risk of VTE

Routine, Once, PACU & Post-op

High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)

|  |   |
|--|---|
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op  |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                 | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min   |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op  |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.  |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:  |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:   |

Mechanical Prophylaxis (Single Response)

|  |  |
|--|--|
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis            | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous       | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous       | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings                                   | Routine, Once, PACU & Post-op  |

High Risk of DVT - Non-Surgical

Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis.

High Risk

|   |                               |
|---|-------------------------------|
| <input type="checkbox"/> High risk of VTE | Routine, Once, PACU & Post-op |
|---|-------------------------------|

High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)

|  |  |
|--|--|
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                 | 30 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |

Mechanical Prophylaxis (Single Response)

|  |  |
|--|--|
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis            | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous       | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous       | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings                                   | Routine, Once, PACU & Post-op  |

High Risk of DVT - Surgical (Hip/Knee)

Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis.

High Risk

|   |                               |
|---|-------------------------------|
| <input type="checkbox"/> High risk of VTE | Routine, Once, PACU & Post-op |
|---|-------------------------------|

High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)

|  |  |
|--|--|
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> apixaban (ELIQUIS) tablet   | 2.5 mg, oral, every 12 hours, Starting S+1, PACU & Post-op<br>Indications:   |
| <input type="checkbox"/> aspirin chewable tablet   | 162 mg, oral, daily, Starting S+1, PACU & Post-op  |
| <input type="checkbox"/> aspirin (ECOTRIN) enteric coated tablet   | 162 mg, oral, daily, Starting S+1, PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - hip arthroplasty   | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - knee arthroplasty  | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty                     | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min.  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                 | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission                               | 10 mg, oral, daily at 0600 (time critical), Starting S+1, PACU & Post-op<br>To be Given on Post Op Day 1.<br>Indications:  |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |

|  |                                     |
|--|-------------------------------------|
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings | <b>"And" Linked Panel</b>           |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous       | Routine, Continuous, PACU & Post-op |
| <input type="checkbox"/> Place antiembolic stockings                                   | Routine, Once, PACU & Post-op       |

**DVT Risk and Prophylaxis Tool (Single Response)**

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

|   |  |
|---|--|
| <input type="checkbox"/> Low Risk of DVT            |  |
| <input type="checkbox"/> Low Risk (Single Response) |  |
| <input type="checkbox"/> Low risk of VTE            | Routine, Once<br>Low risk: Due to low risk, no VTE prophylaxis is needed.<br>Will encourage early ambulation<br>PACU & Post-op |

|  |  |
|--|--|
| <input type="checkbox"/> Moderate Risk of DVT - Surgical   |  |
| Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated. |  |

|   |                               |
|---|-------------------------------|
| <input type="checkbox"/> Moderate Risk        |                               |
| <input type="checkbox"/> Moderate risk of VTE | Routine, Once, PACU & Post-op |

|   |  |
|---|--|
| <input type="checkbox"/> Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation                     | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis                          | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |

|  |  |
|--|--|
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min                             | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |

|  |  |
|--|--|
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                                | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)               | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> Moderate Risk of DVT - Non-Surgical   |  |
| Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated. |  |
| <input type="checkbox"/> Moderate Risk   |  |
| <input type="checkbox"/> Moderate risk of VTE  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)  |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                               | 30 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   |



|  |  |
|--|--|
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  | 40 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)                             | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> High Risk of DVT - Surgical<br>Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis. |  |
| <input type="checkbox"/> High Risk   |  |
| <input type="checkbox"/> High risk of VTE  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)  |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |

|  |   |
|--|---|
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op  |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.  |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:  |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:   |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |   |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op   |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op   |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op   |
| <input type="checkbox"/> High Risk of DVT - Non-Surgical   |   |
| Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis.                             |   |
| <input type="checkbox"/> High Risk   |   |
| <input type="checkbox"/> High risk of VTE  | Routine, Once, PACU & Post-op   |
| <input type="checkbox"/> High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)  |   |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op  |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCl LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S<br>For Patients with CrCl LESS than 30 mL/min  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                 | 30 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min   |

|   |  |
|---|--|
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection   | 2.5 mg, subcutaneous, daily, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection  | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)  | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet   | oral, daily at 1700 (time critical), PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)   | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)   |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis   | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous  | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings  | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous  | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> High Risk of DVT - Surgical (Hip/Knee)<br>Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis. |  |
| <input type="checkbox"/> High Risk  |  |
| <input type="checkbox"/> High risk of VTE   | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)  |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation   | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis  | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> apixaban (ELIQUIS) tablet  | 2.5 mg, oral, every 12 hours, Starting S+1, PACU & Post-op<br>Indications:   |
| <input type="checkbox"/> aspirin chewable tablet  | 162 mg, oral, daily, Starting S+1, PACU & Post-op  |
| <input type="checkbox"/> aspirin (ECOTRIN) enteric coated tablet  | 162 mg, oral, daily, Starting S+1, PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)   |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - hip arthroplasty  | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - knee arthroplasty   | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty  | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min.  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min  | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.  |

|  |  |
|--|--|
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission                               | 10 mg, oral, daily at 0600 (time critical), Starting S+1, PACU & Post-op<br>To be Given on Post Op Day 1.<br>Indications:  |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op  |

## Labs

### Labs POD #1

|   |  |
|---|--|
| <input type="checkbox"/> CBC with platelet and differential | AM draw repeats For 2 Occurrences, Post-op |
| <input type="checkbox"/> CBC hemogram                       | AM draw repeats For 2 Occurrences, Post-op |
| <input type="checkbox"/> Basic metabolic panel              | AM draw repeats For 2 Occurrences, Post-op |

## Cardiology

## Imaging

### X-Ray

|  |                                      |
|--|--------------------------------------|
| <input type="checkbox"/> XR Hip 2-3 View Left                  | Routine, 1 time imaging For 1 , PACU |
| <input type="checkbox"/> XR Hip 2-3 View Right                 | Routine, 1 time imaging For 1 , PACU |
| <input type="checkbox"/> Hips Bilateral Ap Lateral W Ap Pelvis | Routine, 1 time imaging For 1 , PACU |
| <input type="checkbox"/> Femur 2 Vw Left                       | Routine, 1 time imaging For 1 , PACU |
| <input type="checkbox"/> Femur 2 Vw Right                      | Routine, 1 time imaging For 1 , PACU |
| <input type="checkbox"/> Tibia Fibula 2 Vw Left                | Routine, 1 time imaging For 1 , PACU |
| <input type="checkbox"/> Tibia Fibula 2 Vw Right               | Routine, 1 time imaging For 1 , PACU |
| <input type="checkbox"/> Knee 1 Or 2 Vw Left                   | Routine, 1 time imaging For 1 , PACU |
| <input type="checkbox"/> Knee 1 Or 2 Vw Right                  | Routine, 1 time imaging For 1 , PACU |

|  |                                      |
|--|--------------------------------------|
| <input type="checkbox"/> Knee 3 Vw Left  | Routine, 1 time imaging For 1 , PACU |
| <input type="checkbox"/> Knee 3 Vw Right | Routine, 1 time imaging For 1 , PACU |

## Other Studies

## Respiratory

## Rehab

## Consults

For Physician Consult orders use sidebar

### Ancillary Consults

|  |  |
|--|--|
| <input type="checkbox"/> Consult to Case Management          | Consult Reason: Discharge Planning<br>Post-op, And post discharge equipment needs. Plan discharge on POD #2-3.         |
| <input type="checkbox"/> Consult to Social Work              | Reason for Consult: Discharge Placement<br>Post-op, And post discharge equipment needs. Plan to discharge on POD #2-3. |
| <input type="checkbox"/> Consult PT eval and treat           | Special Instructions: evaluate equipment needs at discharge<br>Weight Bearing Status:                                  |
| <input type="checkbox"/> Consult OT eval and treat           | Special Instructions: Instruct on use of hip kit.<br>Weight Bearing Status:  |
| <input type="checkbox"/> Consult to Fracture Liaison Service | Clinical Indications:<br>Post-op   |

## Additional Orders